Drugs in Space III: Chiron's PEG-IL-2, Schering's Intron A among experiments on board the shuttle Discovery.
DRUGS IN SPACE III: CHIRON's PROLEUKIN PEG-IL-2 is among the drug compounds that will be tested in SPACEHAB-3 aboard the NASA shuttle Discovery, which launched from the Kennedy Space Center on Feb. 3. The "IMMUNE-2" experiment will test treatment of immune system deficiencies in rats administered Proleukin PEG-IL-2 (polyethylene glycosylated-interleukin-2) as a possible treatment for AIDS and other immunosuppresive diseases. Both IL-2 and PEG-IL-2 are in clinical trials for AIDS. PEG-IL-2, whose duration of effect is 10-fold longer than IL-2, is approved for refractory renal cancer.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth